Neural organoids protect engineered heart tissues from glucolipotoxicity by transferring versican in a co-culture system

分享:

简介:

  • 作者: Baochen Bai, Jiting Li, Ze Wang, Yuhan Yang, Jieqing He, Gonglie Chen, Yufan Zhang, Yan Qi, Zhongjun Wan, Lin Cai, Run Wang, Kai Wang, Dongyu Zhao, Jingzhong Zhang, Weihua Huang, Ronald X Xu, Mingzhai Sun, Xiao Han, Yan Liu, Donghui Zhang, Wanying Zhu, Jian Liu, Yuxuan Guo
  • 杂志: BioRxiv
  • Doi: https://www.doi.org/10.1101/2025.05.07.652597
  • 出版日期: 2025-05-12

论文中使用的产品/服务

询价

摘要

Metabolic disorders could cause dysregulated glucose and lipid at the systemic level, but how inter-tissue/organ communications contribute to glucolipotoxicity is difficult to dissect in animal models. To solve this problem, myocardium and nerve tissues were modeled by 3D engineered heart tissues (EHTs) and neural organoids (NOs), which were co-cultured in a generalized medium with normal or elevated glucose/fatty acid contents. Morphology, gene expression, cell death and functional assessments detected no apparent alterations of EHTs and NOs in co-culture under normal conditions. By contrast, NOs significantly ameliorated glucolipotoxicity in EHTs. Transcriptomic and protein secretion assays identified the extracellular matrix protein versican as a key molecule that was transferred from NOs into EHTs in the high-glucose/fatty acid condition. Recombinant versican protein treatment was sufficient to reduce glucolipotoxicity in EHTs. Adeno-associated virus-delivered versican overexpression was sufficient to ameliorate cardiac dysfunction in a murine model of diabetic cardiomyopathy. These data provide the proof-of-concept evidence that inter-tissue/organ communications exist in the co-culture of engineered tissues and organoids, which could be systemically studied to explore potential pathological mechanisms and therapeutic strategies for multi-organ diseases in vitro.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*